VLA1601-102, NCT06334393: Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults |
|
|
| Recruiting | 1 | 150 | US | VLA1601, CpG 1018®, 3M-052-AF | Valneva Austria GmbH | Zika, Zika Virus Infection | 12/24 | 12/25 | | |